<DOC>
	<DOCNO>NCT00928811</DOCNO>
	<brief_summary>The study undertaken explore safety use Simulect monthly dose interval reduce need high dose/level CNI 's Prograf .</brief_summary>
	<brief_title>Study Evaluate Safety Chronic Administration Simulect Subjects Receiving First Kidney Transplant</brief_title>
	<detailed_description>The use CNI 's kidney transplantation associate typical adverse effect potential contribution progressive impairment renal function , hypertension , metabolic abnormality . The study consist run-in phase ( 1 month ) , treatment phase ( 11 month ) safety assessment phase ( 1 month ) .</detailed_description>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female 1875 First kidney transplant living decease donor Receiving CNI MPA Able tolerate full dose MPA Calculated glomerular filtration rate &gt; =30ml/min CockcroftGault equation Able tolerate renal graft biopsy Provided write , informed consent Females childbearing potential must negative pregnancy test within 48 hour prior first Simulect administration Known hypersensitivity Simulect Current preform PRA &gt; 10 % Multi organ second kidney transplant Use investigational immunosuppressive drug within 1 month inclusion Female patient pregnant , lactate child bear potential practicing two approve method birth control Known malignancy history malignancy excise basal squamous cell carcinoma skin HBV , HCV , HIV positive patient Current severe infection Receiving organ extend criterion donor per United Network Organ Sharing ( UNOS ) guideline Dialysis dependent one month post transplant Live far away transplant center adequate follow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Simulect</keyword>
	<keyword>de novo kidney transplant subject</keyword>
	<keyword>calcineurin inhibitor</keyword>
	<keyword>Prograf</keyword>
</DOC>